ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX Total Non-current Assets
All assets not expected to be converted to cash within one year.
Total Non-current Assets history
Currency unavailable · from the balance sheet
No Total Non-current Assets data reported for this period type.
Total Non-current Assets vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $156.84M USD | -4.6% | +36.3% | 53.2% | |
| Mar 2026 | $148.45M USD | +3.0% | -2.3% | 60.7% | |
| Mar 2026 | $76.6M USD | +145.9% | +111.0% | 17.3% | |
| Mar 2026 | $28.53M USD | -46.2% | -14.2% | 11.6% | |
| Mar 2026 | $22.27M USD | -26.7% | -20.9% | 3.8% | |
| Mar 2026 | $12.27M USD | -20.9% | +5.7% | 10.7% | |
| Mar 2026 | €12.06M EUR | -17.9% | -9.2% | 12.2% | |
| Mar 2026 | $6.8M USD | — | — | 2.3% | |
| Mar 2026 | $983K USD | -18.0% | -2.3% | 0.5% | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | -18.0% | -2.3% | 11.6% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.